Pesticide governance will not significantly weaken the price increase trend throughout the year

This year, the environmental protection management of the pesticide industry is carried out throughout the year, and the intensity is different from and stronger than the previous environmental protection
.
Our expectation for the whole year of this year is that the price increase trend will not be significantly weakened, the average product price will stand at a high level year-on-year, and the number and timing of price increases are expected to exceed expectations
.
Suggested attention: dicamba, pyrethroid, imidacloprid, mancozeb, azoxystrobin, chlorothalonil, carbendazim, glufosinate and other varieties
.
Recommended attention: Dicamba: 1.
Cost benzene price increase + stricter environmental protection, on the one hand, led to cautious supply, on the other hand, increased production costs; 2.
Due to Monsanto and Yangnong vigorously promoting dicamba, some of the planned production capacity in the industry chose to give up this year.
The increase in the supply side is actually limited; third, the demand side of genetically modified products is gradually entering the stocking, and in summary, the product price is expected to be boosted
.
Pyrethrin: Due to the shortage of intermediates Kungfu acid, ether aldehyde (Kongfu pyrethrin intermediate), and bifenthrin (bifenthrin intermediate), the supply of Kungfu and bifenthrin continues to rise, and the price of Kungfu and bifenthrin continues to rise from 140,000/ The ton rose to 173,000, and biphenyl rose from 180,000 to the current 220,000.
It is expected to continue to rise.
The cost of ether aldehyde has a limited increase and the price difference has widened significantly
.
Imidacloprid/acetamiprid: Environmental protection has increased the cost of resuming production in the industry.
Warm winter + early Spring Festival + first half of the year eliminated the impact of El Niño.
Orders for imidacloprid/acetamiprid are strong, and the price increase is expected to reach new highs
.
Mancozeb: The Hebei plant has not started, and the price of raw material ethylenediamine has risen.
The demand for mancozeb is tight and the price is expected to increase
.
Azoxystrobin: The intermediate benzofuranone and 4,6-dihydroxypyrimidine are in short supply.
The azoxystrobin industry is losing money as a whole.
Most of the small production capacity in Hebei is facing rectification.
Azoxystrobin is expected to usher in another spring
.
Carbendazim: The main domestic production capacity is in Ningxia.
Due to environmental issues, most of the installations have low operating rates and are difficult to recover in the short term.
At the same time, the intermediate o-phenylenediamine is in short supply and the supply of carbendazim is tight
.
Glufosinate-ammonium: The demand for substitution of paraquat is gradually opening up, and the main production capacity of Hebei Ruikai has been limited but has not started.
The mismatch of supply and demand glufosinate-ammonium is tight
.